Bisphosphonate-related osteonecrosis of the jaw in four Nordic countries and an indication of under-reporting

Acta Odontologica Scandinavica

Volumn 71, Issue 6, 2013, Pages 1386-1390

  Krüger, Tormod B ^a   Sharikabad, Mohammad N ^b   Herlofson, Bente Brokstad ^a,c  

^a UNIVERSITY OF OSLO   (Norway)

^b Norwegian Medicines Agency   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Adverse drug reaction; Antiresorptive drugs; Oral health; Osteonecrosis of the jaw; Pharmacovigilance

Indexed keywords

ARTICLE; E-MAIL; HUMAN; INCIDENCE; JAW OSTEONECROSIS; QUESTIONNAIRE; SCANDINAVIA;

BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; ELECTRONIC MAIL; HUMANS; INCIDENCE; QUESTIONNAIRES; SCANDINAVIA;

EID: 84887224792     PISSN: 00016357     EISSN: 15023850     Source Type: Journal    
DOI: 10.3109/00016357.2013.764007     Document Type: Article

References (19)

1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1999;348:1535-41.
2. Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Stürzenbaum S, et al. Bisphosphonate-related osteonecrosis of the jaws-Characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg 2012;40:303-9.
3. Advisory Task Force on Bisphosphonate. Related Osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofacial Surg 2007;65: 369-76.
4. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-17.
5. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-7.
6. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253-4.
7. Thirstrup S. CHMP assessment report on bisphosphonates and osteonecrosis of the jaw. The European Medicines Agency; 2010. Available online at www.ema.europa.eu/docs/en-GB/document-library/Report/2010/01/WC500051428.pdf. Accessed 10 April 2012.
8. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; Task Force on bisphosphonate-related osteonecrosis of the jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw-2009 update. Aust Endod J 2009;35:119-30.
9. Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Predicting Risk of Osteonecrosis of the Jaw with Oral Bisphosphonate Exposure (PROBE) Investigators. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010;68: 243-53.
10. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: WHO, 2002. online Available online at http://apps.who.int/medicinedocs/en/d/Js4893e/.accessed 2 April 2012.
11. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010. Available online at http://ec. europa.eu/health/files/eudralex/ vol-1/dir-2010-84/dir-2010-84-en.pdf. Accessed 20 March 2012.
12. Vollset SE. Confidence intervals for a binomial proportion. Stat Med 1993;12:809-24.
13. The Uppsala Monitoring Centre. Pharmacovigilance, The WHO programme; 2012. Available online at http://www. who-umc.org/. Accessed 2 April 2012.
14. González-Rubio F, Calderón-Larrañaga A, Poblador-Plou B, Navarro-Pemán C, López-Cabañas A, Prados-Torres A. Underreporting of recognized adverse drug reactions by primary care physicians: an exploratory study. Pharmacoepidemiol Drug Saf 2011;20:1287-94.
15. Cox AR, Anton C, McDowell SE, Marriott JF, Ferner RE. Correlates of spontaneous reporting of adverse drug reactions within primary care: the paradox of low prescribers who are high reporters. Br J Clin Pharmacol 2010;69:529-34.
16. Sharikabad M. Bisfosfonatrelatert kjevebensnekrose; europeiske og norske erfaringer. Norsk Farmaceutisk Tidsskr 2012;1:26-9.
17. Heeley E, Riley J, Layton D, Wilton LV, Shakir SA. Prescription-event monitoring and reporting of adverse drug reactions. Lancet 2011;358:1872-3.
18. Werner CA. U.S. Census Bureau brief on data from the 2010 Census. 2010. Available online at http://www.census. gov/prod/cen2010/briefs/c2010br-09.pdf. Accessed 7 March 2012.
19. Schnatz PF. The 2010 North American Menopause Society position statement: updates on screening, prevention and management of postmenopausal osteoporosis. Conn Med 2011;75:485-7.